Core Viewpoint - The Schall Law Firm is investigating claims against Tvardi Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Tvardi Therapeutics issued false or misleading statements or failed to disclose critical information to investors [2]. - A press release from Tvardi on October 13, 2025, indicated that the Phase 2 REVERT trial for TTI-101 did not meet its goals, leading to a significant drop in share price by nearly 84% on the same day [2]. Group 2: Investor Participation - Shareholders who experienced losses are encouraged to participate in the investigation and can contact the Schall Law Firm for further discussion of their rights [3].